Vical Inc (VICL)

2.66
NASDAQ : Health Care
Prev Close 2.65
Day Low/High 2.56 / 2.73
52 Wk Low/High 2.05 / 4.50
Avg Volume 76.10K
Exchange NASDAQ
Shares Outstanding 11.10M
Market Cap 29.40M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Vical Reports First Quarter 2017 Financial Results

VL-2397 Data to be presented at ASM Microbe 2017 Conference in June

Vical's Phase 1/2 Trial Data Presented At ASM 2016 Shows Bivalent Vaccine Imparts Reduction In Genital Herpes Lesions Durable To 9 Months

Vical's Phase 1/2 Trial Data Presented At ASM 2016 Shows Bivalent Vaccine Imparts Reduction In Genital Herpes Lesions Durable To 9 Months

Vical plans to advance the bivalent vaccine to a Phase 2 trial in 2016 and maintains current financial guidance for 2016